- Home
- NUVL vs AXS Comparison
NUVL vs AXS Comparison
Compare NUVL & AXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- AXS
- Stock Information
- Founded
- NUVL 2017
- AXS 2001
- Country
- NUVL United States
- AXS Bermuda
- Employees
- NUVL N/A
- AXS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- AXS Property-Casualty Insurers
- Sector
- NUVL Health Care
- AXS Finance
- Exchange
- NUVL Nasdaq
- AXS Nasdaq
- Market Cap
- NUVL 6.7B
- AXS 7.5B
- IPO Year
- NUVL 2021
- AXS N/A
- Fundamental
- Price
- NUVL $75.84
- AXS $90.22
- Analyst Decision
- NUVL Strong Buy
- AXS Strong Buy
- Analyst Count
- NUVL 11
- AXS 8
- Target Price
- NUVL $112.36
- AXS $99.25
- AVG Volume (30 Days)
- NUVL 558.9K
- AXS 576.2K
- Earning Date
- NUVL 02-25-2025
- AXS 01-29-2025
- Dividend Yield
- NUVL N/A
- AXS 1.95%
- EPS Growth
- NUVL N/A
- AXS 15.01
- EPS
- NUVL N/A
- AXS 7.19
- Revenue
- NUVL N/A
- AXS $5,967,185,000.00
- Revenue This Year
- NUVL N/A
- AXS N/A
- Revenue Next Year
- NUVL N/A
- AXS $8.34
- P/E Ratio
- NUVL N/A
- AXS $12.55
- Revenue Growth
- NUVL N/A
- AXS 6.37
- 52 Week Low
- NUVL $61.80
- AXS $54.97
- 52 Week High
- NUVL $113.51
- AXS $94.89
- Technical
- Relative Strength Index (RSI)
- NUVL 38.09
- AXS 56.40
- Support Level
- NUVL $69.58
- AXS $83.90
- Resistance Level
- NUVL $78.18
- AXS $89.34
- Average True Range (ATR)
- NUVL 3.03
- AXS 1.60
- MACD
- NUVL 0.04
- AXS 0.08
- Stochastic Oscillator
- NUVL 50.40
- AXS 90.41
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a property and casualty insurance company that provides various products and services to clients and distribution partners. The company has operating subsidiaries and branch networks based in Bermuda, the United States, Canada, Europe, and Singapore. Its business consists of two distinct global underwriting platforms, AXIS Insurance, and AXIS Reinsurance. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks.